nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—ABCC4—Methotrexate—psoriatic arthritis	0.0578	0.0925	CbGbCtD
Sorafenib—ABCC2—Dexamethasone—psoriatic arthritis	0.0428	0.0685	CbGbCtD
Sorafenib—ABCG2—Dexamethasone—psoriatic arthritis	0.0387	0.0619	CbGbCtD
Sorafenib—ABCB1—Methylprednisolone—psoriatic arthritis	0.0369	0.059	CbGbCtD
Sorafenib—ABCC2—Methotrexate—psoriatic arthritis	0.0344	0.055	CbGbCtD
Sorafenib—ABCG2—Methotrexate—psoriatic arthritis	0.0311	0.0498	CbGbCtD
Sorafenib—CYP3A7—Dexamethasone—psoriatic arthritis	0.0286	0.0457	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Dexamethasone—psoriatic arthritis	0.0286	0.0457	CbGbCtD
Sorafenib—CYP2C19—Prednisone—psoriatic arthritis	0.0277	0.0443	CbGbCtD
Sorafenib—CYP2B6—Dexamethasone—psoriatic arthritis	0.0272	0.0436	CbGbCtD
Sorafenib—ABCB1—Betamethasone—psoriatic arthritis	0.024	0.0384	CbGbCtD
Sorafenib—ABCB1—Prednisolone—psoriatic arthritis	0.0237	0.0379	CbGbCtD
Sorafenib—ABCB1—Prednisone—psoriatic arthritis	0.0223	0.0358	CbGbCtD
Sorafenib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0221	0.0354	CbGbCtD
Sorafenib—CYP3A5—Dexamethasone—psoriatic arthritis	0.0214	0.0343	CbGbCtD
Sorafenib—CYP2C8—Dexamethasone—psoriatic arthritis	0.0206	0.033	CbGbCtD
Sorafenib—CYP2C19—Dexamethasone—psoriatic arthritis	0.0173	0.0277	CbGbCtD
Sorafenib—CYP3A4—Triamcinolone—psoriatic arthritis	0.0167	0.0268	CbGbCtD
Sorafenib—CYP2C9—Dexamethasone—psoriatic arthritis	0.0144	0.023	CbGbCtD
Sorafenib—CYP3A4—Betamethasone—psoriatic arthritis	0.0144	0.023	CbGbCtD
Sorafenib—CYP3A4—Prednisolone—psoriatic arthritis	0.0142	0.0227	CbGbCtD
Sorafenib—ABCB1—Dexamethasone—psoriatic arthritis	0.014	0.0223	CbGbCtD
Sorafenib—CYP3A4—Prednisone—psoriatic arthritis	0.0134	0.0214	CbGbCtD
Sorafenib—CYP2D6—Dexamethasone—psoriatic arthritis	0.0131	0.021	CbGbCtD
Sorafenib—ABCB1—Methotrexate—psoriatic arthritis	0.0112	0.0179	CbGbCtD
Sorafenib—CYP3A4—Dexamethasone—psoriatic arthritis	0.00836	0.0134	CbGbCtD
Sorafenib—MUSK—tendon—psoriatic arthritis	0.00331	0.123	CbGeAlD
Sorafenib—TAOK2—tendon—psoriatic arthritis	0.0014	0.0523	CbGeAlD
Sorafenib—AURKC—tendon—psoriatic arthritis	0.00139	0.0519	CbGeAlD
Sorafenib—ZAK—tendon—psoriatic arthritis	0.00122	0.0456	CbGeAlD
Sorafenib—HIPK3—tendon—psoriatic arthritis	0.0012	0.0446	CbGeAlD
Sorafenib—BRAF—tendon—psoriatic arthritis	0.00107	0.04	CbGeAlD
Sorafenib—EPHX2—tendon—psoriatic arthritis	0.00103	0.0382	CbGeAlD
Sorafenib—RAF1—skin of body—psoriatic arthritis	0.000939	0.035	CbGeAlD
Sorafenib—EPHB6—skin of body—psoriatic arthritis	0.000933	0.0348	CbGeAlD
Sorafenib—FGFR1—tendon—psoriatic arthritis	0.000912	0.034	CbGeAlD
Sorafenib—MAP3K7—tendon—psoriatic arthritis	0.000863	0.0322	CbGeAlD
Sorafenib—MKNK2—tendon—psoriatic arthritis	0.000837	0.0312	CbGeAlD
Sorafenib—RET—tendon—psoriatic arthritis	0.000816	0.0304	CbGeAlD
Sorafenib—CSF1R—skin of body—psoriatic arthritis	0.000779	0.029	CbGeAlD
Sorafenib—RALBP1—tendon—psoriatic arthritis	0.000756	0.0282	CbGeAlD
Sorafenib—FLT1—tendon—psoriatic arthritis	0.000719	0.0268	CbGeAlD
Sorafenib—RAF1—tendon—psoriatic arthritis	0.000715	0.0266	CbGeAlD
Sorafenib—EPHB6—tendon—psoriatic arthritis	0.000711	0.0265	CbGeAlD
Sorafenib—KIT—skin of body—psoriatic arthritis	0.000707	0.0264	CbGeAlD
Sorafenib—PDGFRB—skin of body—psoriatic arthritis	0.000691	0.0258	CbGeAlD
Sorafenib—STK10—tendon—psoriatic arthritis	0.00068	0.0254	CbGeAlD
Sorafenib—PDGFRA—tendon—psoriatic arthritis	0.000674	0.0251	CbGeAlD
Sorafenib—MAP3K7—TNF alpha Signaling Pathway—TNFRSF1B—psoriatic arthritis	0.000632	0.00694	CbGpPWpGaD
Sorafenib—RET—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000613	0.00673	CbGpPWpGaD
Sorafenib—MAPK11—IL6-mediated signaling events—CRP—psoriatic arthritis	0.000611	0.00671	CbGpPWpGaD
Sorafenib—KDR—tendon—psoriatic arthritis	0.000608	0.0227	CbGeAlD
Sorafenib—MAP2K5—tendon—psoriatic arthritis	0.000608	0.0227	CbGeAlD
Sorafenib—PDGFRA—Allograft Rejection—IL17A—psoriatic arthritis	0.000602	0.00661	CbGpPWpGaD
Sorafenib—RAF1—Leptin signaling pathway—REL—psoriatic arthritis	0.000599	0.00657	CbGpPWpGaD
Sorafenib—CSF1R—tendon—psoriatic arthritis	0.000593	0.0221	CbGeAlD
Sorafenib—MAP3K7—IL-6 signaling pathway—CRP—psoriatic arthritis	0.000592	0.00649	CbGpPWpGaD
Sorafenib—MAPK11—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.000591	0.00649	CbGpPWpGaD
Sorafenib—MAP3K7—Downstream TCR signaling—HLA-DRB1—psoriatic arthritis	0.000588	0.00646	CbGpPWpGaD
Sorafenib—MAP3K7—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.000573	0.00629	CbGpPWpGaD
Sorafenib—PDGFRA—Allograft Rejection—IL12B—psoriatic arthritis	0.00056	0.00615	CbGpPWpGaD
Sorafenib—HTR2B—skin of body—psoriatic arthritis	0.000547	0.0204	CbGeAlD
Sorafenib—MAPK11—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000535	0.00587	CbGpPWpGaD
Sorafenib—MAPK11—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.000535	0.00587	CbGpPWpGaD
Sorafenib—MAP3K7—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.000533	0.00585	CbGpPWpGaD
Sorafenib—MAPK11—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.00053	0.00582	CbGpPWpGaD
Sorafenib—PDGFRB—tendon—psoriatic arthritis	0.000526	0.0196	CbGeAlD
Sorafenib—MAPK11—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.00052	0.00571	CbGpPWpGaD
Sorafenib—RAF1—TCR Signaling Pathway—REL—psoriatic arthritis	0.000518	0.00568	CbGpPWpGaD
Sorafenib—RAF1—TNF alpha Signaling Pathway—REL—psoriatic arthritis	0.000509	0.00558	CbGpPWpGaD
Sorafenib—MAPK11—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.000502	0.00551	CbGpPWpGaD
Sorafenib—MAPK11—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000494	0.00542	CbGpPWpGaD
Sorafenib—RAF1—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.000488	0.00535	CbGpPWpGaD
Sorafenib—ZAK—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000487	0.00534	CbGpPWpGaD
Sorafenib—MAP3K7—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000482	0.0053	CbGpPWpGaD
Sorafenib—MAP3K7—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.000482	0.00529	CbGpPWpGaD
Sorafenib—RAF1—TNF alpha Signaling Pathway—TNFRSF1B—psoriatic arthritis	0.00048	0.00527	CbGpPWpGaD
Sorafenib—MAP3K7—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.000478	0.00525	CbGpPWpGaD
Sorafenib—MAPK11—MyD88-independent cascade—NOD2—psoriatic arthritis	0.000474	0.0052	CbGpPWpGaD
Sorafenib—MAP3K7—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.000469	0.00515	CbGpPWpGaD
Sorafenib—MAPK11—ATF-2 transcription factor network—NOS2—psoriatic arthritis	0.000464	0.0051	CbGpPWpGaD
Sorafenib—MAP3K7—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.000453	0.00497	CbGpPWpGaD
Sorafenib—MAP3K7—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.000445	0.00489	CbGpPWpGaD
Sorafenib—MAP3K7—EBV LMP1 signaling—TNF—psoriatic arthritis	0.000442	0.00485	CbGpPWpGaD
Sorafenib—MAP3K7—TCR signaling—HLA-DRB1—psoriatic arthritis	0.00044	0.00483	CbGpPWpGaD
Sorafenib—RAF1—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.000436	0.00478	CbGpPWpGaD
Sorafenib—MAP3K7—MyD88-independent cascade—NOD2—psoriatic arthritis	0.000427	0.00469	CbGpPWpGaD
Sorafenib—MAPK11—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.000426	0.00468	CbGpPWpGaD
Sorafenib—MAPK11—Rac1/Pak1/p38/MMP-2 pathway—NOS2—psoriatic arthritis	0.00042	0.00461	CbGpPWpGaD
Sorafenib—ABCC4—tendon—psoriatic arthritis	0.000419	0.0156	CbGeAlD
Sorafenib—MAPK11—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.000417	0.00458	CbGpPWpGaD
Sorafenib—HTR2B—tendon—psoriatic arthritis	0.000417	0.0155	CbGeAlD
Sorafenib—KIT—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000415	0.00456	CbGpPWpGaD
Sorafenib—MAP3K7—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000415	0.00456	CbGpPWpGaD
Sorafenib—TAOK2—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000414	0.00454	CbGpPWpGaD
Sorafenib—Mental disorder—Methylprednisolone—psoriatic arthritis	0.00041	0.00159	CcSEcCtD
Sorafenib—Erythema—Triamcinolone—psoriatic arthritis	0.000408	0.00159	CcSEcCtD
Sorafenib—Erythema—Methylprednisolone—psoriatic arthritis	0.000407	0.00158	CcSEcCtD
Sorafenib—Malnutrition—Methylprednisolone—psoriatic arthritis	0.000407	0.00158	CcSEcCtD
Sorafenib—Acute coronary syndrome—Prednisone—psoriatic arthritis	0.000407	0.00158	CcSEcCtD
Sorafenib—Angioedema—Prednisolone—psoriatic arthritis	0.000405	0.00158	CcSEcCtD
Sorafenib—ABCC2—tendon—psoriatic arthritis	0.000405	0.0151	CbGeAlD
Sorafenib—Neuropathy peripheral—Prednisone—psoriatic arthritis	0.000404	0.00157	CcSEcCtD
Sorafenib—Myocardial infarction—Prednisone—psoriatic arthritis	0.000404	0.00157	CcSEcCtD
Sorafenib—Breast disorder—Methotrexate—psoriatic arthritis	0.000404	0.00157	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Methotrexate—psoriatic arthritis	0.000403	0.00157	CcSEcCtD
Sorafenib—MAPK11—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.000401	0.0044	CbGpPWpGaD
Sorafenib—Dysgeusia—Triamcinolone—psoriatic arthritis	0.0004	0.00155	CcSEcCtD
Sorafenib—MAP3K7—Signaling by Interleukins—NOD2—psoriatic arthritis	0.000398	0.00437	CbGpPWpGaD
Sorafenib—Syncope—Prednisolone—psoriatic arthritis	0.000398	0.00155	CcSEcCtD
Sorafenib—PDGFRA—ATF-2 transcription factor network—NOS2—psoriatic arthritis	0.000396	0.00435	CbGpPWpGaD
Sorafenib—FGFR1—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000394	0.00433	CbGpPWpGaD
Sorafenib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000393	0.00432	CbGpPWpGaD
Sorafenib—Loss of consciousness—Prednisolone—psoriatic arthritis	0.00039	0.00152	CcSEcCtD
Sorafenib—PDGFRA—Allograft Rejection—HLA-B—psoriatic arthritis	0.000389	0.00427	CbGpPWpGaD
Sorafenib—Angiopathy—Dexamethasone—psoriatic arthritis	0.000386	0.0015	CcSEcCtD
Sorafenib—Angiopathy—Betamethasone—psoriatic arthritis	0.000386	0.0015	CcSEcCtD
Sorafenib—MAP3K7—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.000384	0.00422	CbGpPWpGaD
Sorafenib—Hypertension—Prednisolone—psoriatic arthritis	0.000383	0.00149	CcSEcCtD
Sorafenib—Arrhythmia—Dexamethasone—psoriatic arthritis	0.00038	0.00148	CcSEcCtD
Sorafenib—Arrhythmia—Betamethasone—psoriatic arthritis	0.00038	0.00148	CcSEcCtD
Sorafenib—Pancreatitis—Methotrexate—psoriatic arthritis	0.000379	0.00147	CcSEcCtD
Sorafenib—MAP3K7—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.000376	0.00413	CbGpPWpGaD
Sorafenib—Alopecia—Betamethasone—psoriatic arthritis	0.000376	0.00146	CcSEcCtD
Sorafenib—Alopecia—Dexamethasone—psoriatic arthritis	0.000376	0.00146	CcSEcCtD
Sorafenib—Angioedema—Triamcinolone—psoriatic arthritis	0.000373	0.00145	CcSEcCtD
Sorafenib—Haemoglobin—Prednisone—psoriatic arthritis	0.000372	0.00145	CcSEcCtD
Sorafenib—Angioedema—Methylprednisolone—psoriatic arthritis	0.000372	0.00145	CcSEcCtD
Sorafenib—Abdominal discomfort—Methotrexate—psoriatic arthritis	0.000371	0.00144	CcSEcCtD
Sorafenib—Haemorrhage—Prednisone—psoriatic arthritis	0.00037	0.00144	CcSEcCtD
Sorafenib—Erythema—Dexamethasone—psoriatic arthritis	0.00037	0.00144	CcSEcCtD
Sorafenib—Erythema—Betamethasone—psoriatic arthritis	0.00037	0.00144	CcSEcCtD
Sorafenib—KIT—B Cell Activation—REL—psoriatic arthritis	0.000367	0.00403	CbGpPWpGaD
Sorafenib—MAP3K7—B Cell Activation—REL—psoriatic arthritis	0.000367	0.00403	CbGpPWpGaD
Sorafenib—Syncope—Triamcinolone—psoriatic arthritis	0.000366	0.00142	CcSEcCtD
Sorafenib—Syncope—Methylprednisolone—psoriatic arthritis	0.000365	0.00142	CcSEcCtD
Sorafenib—KIT—DAP12 interactions—HLA-C—psoriatic arthritis	0.000365	0.00401	CbGpPWpGaD
Sorafenib—Connective tissue disorder—Prednisone—psoriatic arthritis	0.000364	0.00142	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.000362	0.00141	CcSEcCtD
Sorafenib—Neutropenia—Methotrexate—psoriatic arthritis	0.000362	0.00141	CcSEcCtD
Sorafenib—MAP3K7—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.000361	0.00397	CbGpPWpGaD
Sorafenib—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.000359	0.00139	CcSEcCtD
Sorafenib—CYP2B6—skin of body—psoriatic arthritis	0.000358	0.0134	CbGeAlD
Sorafenib—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.000358	0.00139	CcSEcCtD
Sorafenib—MAPK11—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000357	0.00392	CbGpPWpGaD
Sorafenib—Shock—Prednisolone—psoriatic arthritis	0.000356	0.00139	CcSEcCtD
Sorafenib—Erectile dysfunction—Methotrexate—psoriatic arthritis	0.000356	0.00138	CcSEcCtD
Sorafenib—Cough—Triamcinolone—psoriatic arthritis	0.000356	0.00138	CcSEcCtD
Sorafenib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—REL—psoriatic arthritis	0.000354	0.00389	CbGpPWpGaD
Sorafenib—Hypertension—Triamcinolone—psoriatic arthritis	0.000352	0.00137	CcSEcCtD
Sorafenib—Hypertension—Methylprednisolone—psoriatic arthritis	0.000352	0.00137	CcSEcCtD
Sorafenib—FGFR1—B Cell Activation—REL—psoriatic arthritis	0.000348	0.00382	CbGpPWpGaD
Sorafenib—Myalgia—Triamcinolone—psoriatic arthritis	0.000347	0.00135	CcSEcCtD
Sorafenib—PDGFRA—B Cell Activation—REL—psoriatic arthritis	0.000347	0.00381	CbGpPWpGaD
Sorafenib—Pneumonia—Methotrexate—psoriatic arthritis	0.000347	0.00135	CcSEcCtD
Sorafenib—Myalgia—Methylprednisolone—psoriatic arthritis	0.000347	0.00135	CcSEcCtD
Sorafenib—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000347	0.00135	CcSEcCtD
Sorafenib—FGFR1—DAP12 interactions—HLA-C—psoriatic arthritis	0.000346	0.0038	CbGpPWpGaD
Sorafenib—PDGFRA—DAP12 interactions—HLA-C—psoriatic arthritis	0.000345	0.00379	CbGpPWpGaD
Sorafenib—Infestation NOS—Methotrexate—psoriatic arthritis	0.000345	0.00134	CcSEcCtD
Sorafenib—Infestation—Methotrexate—psoriatic arthritis	0.000345	0.00134	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000344	0.00134	CcSEcCtD
Sorafenib—Flushing—Prednisone—psoriatic arthritis	0.000344	0.00134	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.000342	0.00133	CcSEcCtD
Sorafenib—Dry mouth—Triamcinolone—psoriatic arthritis	0.00034	0.00132	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—psoriatic arthritis	0.000339	0.00132	CcSEcCtD
Sorafenib—Angioedema—Dexamethasone—psoriatic arthritis	0.000338	0.00132	CcSEcCtD
Sorafenib—Angioedema—Betamethasone—psoriatic arthritis	0.000338	0.00132	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—psoriatic arthritis	0.000336	0.00131	CcSEcCtD
Sorafenib—Angiopathy—Prednisone—psoriatic arthritis	0.000336	0.00131	CcSEcCtD
Sorafenib—Immune system disorder—Prednisone—psoriatic arthritis	0.000335	0.0013	CcSEcCtD
Sorafenib—CDK7—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000334	0.00366	CbGpPWpGaD
Sorafenib—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.000333	0.00129	CcSEcCtD
Sorafenib—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.000332	0.00129	CcSEcCtD
Sorafenib—Syncope—Betamethasone—psoriatic arthritis	0.000332	0.00129	CcSEcCtD
Sorafenib—Syncope—Dexamethasone—psoriatic arthritis	0.000332	0.00129	CcSEcCtD
Sorafenib—Arrhythmia—Prednisone—psoriatic arthritis	0.000331	0.00129	CcSEcCtD
Sorafenib—Infection—Triamcinolone—psoriatic arthritis	0.000331	0.00129	CcSEcCtD
Sorafenib—Infection—Methylprednisolone—psoriatic arthritis	0.00033	0.00128	CcSEcCtD
Sorafenib—PDGFRA—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.00033	0.00362	CbGpPWpGaD
Sorafenib—Shock—Triamcinolone—psoriatic arthritis	0.000328	0.00127	CcSEcCtD
Sorafenib—Alopecia—Prednisone—psoriatic arthritis	0.000327	0.00127	CcSEcCtD
Sorafenib—Shock—Methylprednisolone—psoriatic arthritis	0.000327	0.00127	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000326	0.00127	CcSEcCtD
Sorafenib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000326	0.00127	CcSEcCtD
Sorafenib—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000325	0.00127	CcSEcCtD
Sorafenib—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000325	0.00127	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—psoriatic arthritis	0.000325	0.00126	CcSEcCtD
Sorafenib—Mental disorder—Prednisone—psoriatic arthritis	0.000324	0.00126	CcSEcCtD
Sorafenib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000323	0.00125	CcSEcCtD
Sorafenib—Erythema—Prednisone—psoriatic arthritis	0.000322	0.00125	CcSEcCtD
Sorafenib—Malnutrition—Prednisone—psoriatic arthritis	0.000322	0.00125	CcSEcCtD
Sorafenib—MAP3K7—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000322	0.00353	CbGpPWpGaD
Sorafenib—Hypertension—Betamethasone—psoriatic arthritis	0.00032	0.00124	CcSEcCtD
Sorafenib—Hypertension—Dexamethasone—psoriatic arthritis	0.00032	0.00124	CcSEcCtD
Sorafenib—Myalgia—Dexamethasone—psoriatic arthritis	0.000315	0.00123	CcSEcCtD
Sorafenib—Myalgia—Betamethasone—psoriatic arthritis	0.000315	0.00123	CcSEcCtD
Sorafenib—PDGFRB—B Cell Activation—REL—psoriatic arthritis	0.000313	0.00343	CbGpPWpGaD
Sorafenib—PDGFRB—DAP12 interactions—HLA-C—psoriatic arthritis	0.000311	0.00342	CbGpPWpGaD
Sorafenib—Haemoglobin—Methotrexate—psoriatic arthritis	0.000311	0.00121	CcSEcCtD
Sorafenib—Pain—Prednisolone—psoriatic arthritis	0.00031	0.0012	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—psoriatic arthritis	0.00031	0.0012	CcSEcCtD
Sorafenib—MAPK11—Innate Immune System—MEFV—psoriatic arthritis	0.000307	0.00337	CbGpPWpGaD
Sorafenib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000306	0.00119	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—psoriatic arthritis	0.000303	0.00118	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.000303	0.00118	CcSEcCtD
Sorafenib—RAF1—Signaling by Interleukins—NOD2—psoriatic arthritis	0.000303	0.00332	CbGpPWpGaD
Sorafenib—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000303	0.00118	CcSEcCtD
Sorafenib—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000302	0.00117	CcSEcCtD
Sorafenib—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000302	0.00117	CcSEcCtD
Sorafenib—Infection—Betamethasone—psoriatic arthritis	0.0003	0.00117	CcSEcCtD
Sorafenib—Infection—Dexamethasone—psoriatic arthritis	0.0003	0.00117	CcSEcCtD
Sorafenib—Anaemia—Prednisone—psoriatic arthritis	0.000298	0.00116	CcSEcCtD
Sorafenib—Shock—Betamethasone—psoriatic arthritis	0.000297	0.00116	CcSEcCtD
Sorafenib—Shock—Dexamethasone—psoriatic arthritis	0.000297	0.00116	CcSEcCtD
Sorafenib—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000297	0.00115	CcSEcCtD
Sorafenib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000296	0.00115	CcSEcCtD
Sorafenib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000296	0.00115	CcSEcCtD
Sorafenib—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000296	0.00115	CcSEcCtD
Sorafenib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000296	0.00115	CcSEcCtD
Sorafenib—Angioedema—Prednisone—psoriatic arthritis	0.000295	0.00115	CcSEcCtD
Sorafenib—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000293	0.00114	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000293	0.00114	CcSEcCtD
Sorafenib—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000292	0.00114	CcSEcCtD
Sorafenib—MAP2K5—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000291	0.00319	CbGpPWpGaD
Sorafenib—RAF1—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.000291	0.00319	CbGpPWpGaD
Sorafenib—Syncope—Prednisone—psoriatic arthritis	0.000289	0.00112	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—psoriatic arthritis	0.000289	0.00112	CcSEcCtD
Sorafenib—Anorexia—Betamethasone—psoriatic arthritis	0.000288	0.00112	CcSEcCtD
Sorafenib—Anorexia—Dexamethasone—psoriatic arthritis	0.000288	0.00112	CcSEcCtD
Sorafenib—Urticaria—Prednisolone—psoriatic arthritis	0.000288	0.00112	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000287	0.00112	CcSEcCtD
Sorafenib—Fatigue—Triamcinolone—psoriatic arthritis	0.000287	0.00112	CcSEcCtD
Sorafenib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000286	0.00111	CcSEcCtD
Sorafenib—Pain—Triamcinolone—psoriatic arthritis	0.000285	0.00111	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisone—psoriatic arthritis	0.000283	0.0011	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—psoriatic arthritis	0.000281	0.00109	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—psoriatic arthritis	0.00028	0.00109	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000279	0.00108	CcSEcCtD
Sorafenib—Hypertension—Prednisone—psoriatic arthritis	0.000278	0.00108	CcSEcCtD
Sorafenib—RAF1—DAP12 interactions—HLA-C—psoriatic arthritis	0.000277	0.00304	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—MEFV—psoriatic arthritis	0.000277	0.00304	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—MEFV—psoriatic arthritis	0.000277	0.00304	CbGpPWpGaD
Sorafenib—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000275	0.00107	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000275	0.00107	CcSEcCtD
Sorafenib—Myalgia—Prednisone—psoriatic arthritis	0.000275	0.00107	CcSEcCtD
Sorafenib—Arthralgia—Prednisone—psoriatic arthritis	0.000275	0.00107	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—psoriatic arthritis	0.000274	0.00106	CcSEcCtD
Sorafenib—MAP3K7—TWEAK Signaling Pathway—TNF—psoriatic arthritis	0.000273	0.003	CbGpPWpGaD
Sorafenib—MAP3K7—FAS pathway and Stress induction of HSP regulation—TNF—psoriatic arthritis	0.000273	0.003	CbGpPWpGaD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000273	0.00106	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000272	0.00106	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—psoriatic arthritis	0.000271	0.00105	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—psoriatic arthritis	0.000269	0.00105	CcSEcCtD
Sorafenib—Erythema—Methotrexate—psoriatic arthritis	0.000269	0.00105	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000267	0.00104	CcSEcCtD
Sorafenib—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000266	0.00103	CcSEcCtD
Sorafenib—Dyspepsia—Betamethasone—psoriatic arthritis	0.000266	0.00103	CcSEcCtD
Sorafenib—Urticaria—Triamcinolone—psoriatic arthritis	0.000265	0.00103	CcSEcCtD
Sorafenib—Urticaria—Methylprednisolone—psoriatic arthritis	0.000264	0.00103	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—psoriatic arthritis	0.000264	0.00103	CcSEcCtD
Sorafenib—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000263	0.00102	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000263	0.00102	CcSEcCtD
Sorafenib—FGFR1—Innate Immune System—MEFV—psoriatic arthritis	0.000263	0.00288	CbGpPWpGaD
Sorafenib—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000263	0.00102	CcSEcCtD
Sorafenib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000263	0.00102	CcSEcCtD
Sorafenib—Decreased appetite—Betamethasone—psoriatic arthritis	0.000263	0.00102	CcSEcCtD
Sorafenib—PDGFRA—Innate Immune System—MEFV—psoriatic arthritis	0.000262	0.00288	CbGpPWpGaD
Sorafenib—Infection—Prednisone—psoriatic arthritis	0.000261	0.00102	CcSEcCtD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.000261	0.00286	CbGpPWpGaD
Sorafenib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000261	0.00101	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000261	0.00101	CcSEcCtD
Sorafenib—Fatigue—Dexamethasone—psoriatic arthritis	0.000261	0.00101	CcSEcCtD
Sorafenib—Fatigue—Betamethasone—psoriatic arthritis	0.000261	0.00101	CcSEcCtD
Sorafenib—Shock—Prednisone—psoriatic arthritis	0.000259	0.00101	CcSEcCtD
Sorafenib—Pain—Betamethasone—psoriatic arthritis	0.000258	0.001	CcSEcCtD
Sorafenib—Pain—Dexamethasone—psoriatic arthritis	0.000258	0.001	CcSEcCtD
Sorafenib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000258	0.001	CcSEcCtD
Sorafenib—Skin disorder—Prednisone—psoriatic arthritis	0.000256	0.000994	CcSEcCtD
Sorafenib—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000254	0.00279	CbGpPWpGaD
Sorafenib—MAP3K7—TNF receptor signaling pathway —TNF—psoriatic arthritis	0.000254	0.00279	CbGpPWpGaD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000253	0.00278	CbGpPWpGaD
Sorafenib—Anorexia—Prednisone—psoriatic arthritis	0.000251	0.000975	CcSEcCtD
Sorafenib—ABCB1—Allograft Rejection—HLA-C—psoriatic arthritis	0.000249	0.00274	CbGpPWpGaD
Sorafenib—Anaemia—Methotrexate—psoriatic arthritis	0.000249	0.000968	CcSEcCtD
Sorafenib—ABCB1—Allograft Rejection—IL13—psoriatic arthritis	0.000248	0.00272	CbGpPWpGaD
Sorafenib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000247	0.000961	CcSEcCtD
Sorafenib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000247	0.000961	CcSEcCtD
Sorafenib—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000245	0.000954	CcSEcCtD
Sorafenib—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000245	0.000952	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—psoriatic arthritis	0.000241	0.000938	CcSEcCtD
Sorafenib—Urticaria—Dexamethasone—psoriatic arthritis	0.00024	0.000933	CcSEcCtD
Sorafenib—Urticaria—Betamethasone—psoriatic arthritis	0.00024	0.000933	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.00024	0.000932	CcSEcCtD
Sorafenib—Dizziness—Prednisolone—psoriatic arthritis	0.000239	0.000931	CcSEcCtD
Sorafenib—Asthenia—Triamcinolone—psoriatic arthritis	0.000239	0.000929	CcSEcCtD
Sorafenib—Body temperature increased—Betamethasone—psoriatic arthritis	0.000239	0.000929	CcSEcCtD
Sorafenib—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000239	0.000929	CcSEcCtD
Sorafenib—Abdominal pain—Betamethasone—psoriatic arthritis	0.000239	0.000929	CcSEcCtD
Sorafenib—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000239	0.000929	CcSEcCtD
Sorafenib—Asthenia—Methylprednisolone—psoriatic arthritis	0.000238	0.000927	CcSEcCtD
Sorafenib—CDK7—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000238	0.00261	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—MEFV—psoriatic arthritis	0.000236	0.00259	CbGpPWpGaD
Sorafenib—Pruritus—Triamcinolone—psoriatic arthritis	0.000236	0.000916	CcSEcCtD
Sorafenib—Cough—Methotrexate—psoriatic arthritis	0.000235	0.000914	CcSEcCtD
Sorafenib—Pruritus—Methylprednisolone—psoriatic arthritis	0.000235	0.000914	CcSEcCtD
Sorafenib—Dyspepsia—Prednisone—psoriatic arthritis	0.000232	0.000901	CcSEcCtD
Sorafenib—RET—SIDS Susceptibility Pathways—TNF—psoriatic arthritis	0.000231	0.00253	CbGpPWpGaD
Sorafenib—Myalgia—Methotrexate—psoriatic arthritis	0.000229	0.000892	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—psoriatic arthritis	0.000229	0.000892	CcSEcCtD
Sorafenib—Decreased appetite—Prednisone—psoriatic arthritis	0.000229	0.000889	CcSEcCtD
Sorafenib—Rash—Prednisolone—psoriatic arthritis	0.000228	0.000888	CcSEcCtD
Sorafenib—Dermatitis—Prednisolone—psoriatic arthritis	0.000228	0.000887	CcSEcCtD
Sorafenib—ABCB1—Allograft Rejection—IL17A—psoriatic arthritis	0.000228	0.0025	CbGpPWpGaD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000228	0.000886	CcSEcCtD
Sorafenib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000227	0.000884	CcSEcCtD
Sorafenib—Fatigue—Prednisone—psoriatic arthritis	0.000227	0.000882	CcSEcCtD
Sorafenib—Headache—Prednisolone—psoriatic arthritis	0.000227	0.000882	CcSEcCtD
Sorafenib—Constipation—Prednisone—psoriatic arthritis	0.000225	0.000875	CcSEcCtD
Sorafenib—Dizziness—Triamcinolone—psoriatic arthritis	0.00022	0.000856	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.00022	0.000855	CcSEcCtD
Sorafenib—MAP3K7—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.00022	0.00241	CbGpPWpGaD
Sorafenib—Dizziness—Methylprednisolone—psoriatic arthritis	0.00022	0.000854	CcSEcCtD
Sorafenib—Infection—Methotrexate—psoriatic arthritis	0.000218	0.000849	CcSEcCtD
Sorafenib—Asthenia—Dexamethasone—psoriatic arthritis	0.000217	0.000843	CcSEcCtD
Sorafenib—Asthenia—Betamethasone—psoriatic arthritis	0.000217	0.000843	CcSEcCtD
Sorafenib—KIT—DAP12 interactions—HLA-B—psoriatic arthritis	0.000216	0.00237	CbGpPWpGaD
Sorafenib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000216	0.000838	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000215	0.000837	CcSEcCtD
Sorafenib—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000215	0.000837	CcSEcCtD
Sorafenib—Nausea—Prednisolone—psoriatic arthritis	0.000215	0.000836	CcSEcCtD
Sorafenib—Pruritus—Dexamethasone—psoriatic arthritis	0.000214	0.000831	CcSEcCtD
Sorafenib—Pruritus—Betamethasone—psoriatic arthritis	0.000214	0.000831	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—psoriatic arthritis	0.000214	0.00083	CcSEcCtD
Sorafenib—ABCB1—Allograft Rejection—IL12B—psoriatic arthritis	0.000212	0.00233	CbGpPWpGaD
Sorafenib—Vomiting—Triamcinolone—psoriatic arthritis	0.000212	0.000823	CcSEcCtD
Sorafenib—Vomiting—Methylprednisolone—psoriatic arthritis	0.000211	0.000821	CcSEcCtD
Sorafenib—RAF1—Innate Immune System—MEFV—psoriatic arthritis	0.00021	0.00231	CbGpPWpGaD
Sorafenib—Rash—Triamcinolone—psoriatic arthritis	0.00021	0.000816	CcSEcCtD
Sorafenib—Dermatitis—Triamcinolone—psoriatic arthritis	0.00021	0.000816	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—psoriatic arthritis	0.00021	0.000815	CcSEcCtD
Sorafenib—Rash—Methylprednisolone—psoriatic arthritis	0.00021	0.000815	CcSEcCtD
Sorafenib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000209	0.000814	CcSEcCtD
Sorafenib—Urticaria—Prednisone—psoriatic arthritis	0.000209	0.000813	CcSEcCtD
Sorafenib—BRAF—Downstream signaling in naïve CD8+ T cells—TNF—psoriatic arthritis	0.000209	0.00229	CbGpPWpGaD
Sorafenib—Headache—Triamcinolone—psoriatic arthritis	0.000209	0.000811	CcSEcCtD
Sorafenib—Headache—Methylprednisolone—psoriatic arthritis	0.000208	0.000809	CcSEcCtD
Sorafenib—Abdominal pain—Prednisone—psoriatic arthritis	0.000208	0.000809	CcSEcCtD
Sorafenib—Body temperature increased—Prednisone—psoriatic arthritis	0.000208	0.000809	CcSEcCtD
Sorafenib—MAP2K5—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000207	0.00228	CbGpPWpGaD
Sorafenib—RAF1—TWEAK Signaling Pathway—TNF—psoriatic arthritis	0.000207	0.00228	CbGpPWpGaD
Sorafenib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000207	0.000804	CcSEcCtD
Sorafenib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000207	0.000804	CcSEcCtD
Sorafenib—FGFR1—DAP12 interactions—HLA-B—psoriatic arthritis	0.000205	0.00225	CbGpPWpGaD
Sorafenib—PDGFRA—DAP12 interactions—HLA-B—psoriatic arthritis	0.000204	0.00224	CbGpPWpGaD
Sorafenib—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.0002	0.000779	CcSEcCtD
Sorafenib—Dizziness—Betamethasone—psoriatic arthritis	0.0002	0.000777	CcSEcCtD
Sorafenib—Dizziness—Dexamethasone—psoriatic arthritis	0.0002	0.000777	CcSEcCtD
Sorafenib—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000198	0.00218	CbGpPWpGaD
Sorafenib—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000198	0.00218	CbGpPWpGaD
Sorafenib—Nausea—Triamcinolone—psoriatic arthritis	0.000198	0.000769	CcSEcCtD
Sorafenib—Nausea—Methylprednisolone—psoriatic arthritis	0.000197	0.000767	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—psoriatic arthritis	0.000196	0.000762	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisone—psoriatic arthritis	0.000194	0.000754	CcSEcCtD
Sorafenib—MKNK1—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000194	0.00213	CbGpPWpGaD
Sorafenib—Dyspepsia—Methotrexate—psoriatic arthritis	0.000194	0.000753	CcSEcCtD
Sorafenib—RAF1—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000193	0.00212	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000192	0.00211	CbGpPWpGaD
Sorafenib—Vomiting—Betamethasone—psoriatic arthritis	0.000192	0.000747	CcSEcCtD
Sorafenib—Vomiting—Dexamethasone—psoriatic arthritis	0.000192	0.000747	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000191	0.000743	CcSEcCtD
Sorafenib—Rash—Betamethasone—psoriatic arthritis	0.000191	0.000741	CcSEcCtD
Sorafenib—Rash—Dexamethasone—psoriatic arthritis	0.000191	0.000741	CcSEcCtD
Sorafenib—Dermatitis—Dexamethasone—psoriatic arthritis	0.00019	0.00074	CcSEcCtD
Sorafenib—Dermatitis—Betamethasone—psoriatic arthritis	0.00019	0.00074	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00019	0.000738	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—psoriatic arthritis	0.00019	0.000737	CcSEcCtD
Sorafenib—Headache—Betamethasone—psoriatic arthritis	0.000189	0.000736	CcSEcCtD
Sorafenib—Headache—Dexamethasone—psoriatic arthritis	0.000189	0.000736	CcSEcCtD
Sorafenib—Asthenia—Prednisone—psoriatic arthritis	0.000189	0.000734	CcSEcCtD
Sorafenib—Pain—Methotrexate—psoriatic arthritis	0.000188	0.000731	CcSEcCtD
Sorafenib—RAF1—Ceramide signaling pathway—TNF—psoriatic arthritis	0.000186	0.00205	CbGpPWpGaD
Sorafenib—Pruritus—Prednisone—psoriatic arthritis	0.000186	0.000724	CcSEcCtD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000186	0.00204	CbGpPWpGaD
Sorafenib—PDGFRB—DAP12 interactions—HLA-B—psoriatic arthritis	0.000184	0.00202	CbGpPWpGaD
Sorafenib—Diarrhoea—Prednisone—psoriatic arthritis	0.00018	0.0007	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.00018	0.000699	CcSEcCtD
Sorafenib—Nausea—Dexamethasone—psoriatic arthritis	0.000179	0.000698	CcSEcCtD
Sorafenib—Nausea—Betamethasone—psoriatic arthritis	0.000179	0.000698	CcSEcCtD
Sorafenib—MAPK11—Immune System—MEFV—psoriatic arthritis	0.000179	0.00196	CbGpPWpGaD
Sorafenib—Urticaria—Methotrexate—psoriatic arthritis	0.000175	0.000679	CcSEcCtD
Sorafenib—Dizziness—Prednisone—psoriatic arthritis	0.000174	0.000677	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—psoriatic arthritis	0.000174	0.000676	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—psoriatic arthritis	0.000174	0.000676	CcSEcCtD
Sorafenib—Vomiting—Prednisone—psoriatic arthritis	0.000167	0.00065	CcSEcCtD
Sorafenib—RAF1—Cardiac Hypertrophic Response—TNF—psoriatic arthritis	0.000167	0.00183	CbGpPWpGaD
Sorafenib—Rash—Prednisone—psoriatic arthritis	0.000166	0.000645	CcSEcCtD
Sorafenib—Dermatitis—Prednisone—psoriatic arthritis	0.000166	0.000644	CcSEcCtD
Sorafenib—Headache—Prednisone—psoriatic arthritis	0.000165	0.000641	CcSEcCtD
Sorafenib—RAF1—DAP12 interactions—HLA-B—psoriatic arthritis	0.000164	0.0018	CbGpPWpGaD
Sorafenib—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000162	0.00063	CcSEcCtD
Sorafenib—KIT—Immune System—MEFV—psoriatic arthritis	0.000161	0.00177	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—MEFV—psoriatic arthritis	0.000161	0.00177	CbGpPWpGaD
Sorafenib—Asthenia—Methotrexate—psoriatic arthritis	0.000158	0.000613	CcSEcCtD
Sorafenib—MAPK11—Innate Immune System—HLA-C—psoriatic arthritis	0.000157	0.00173	CbGpPWpGaD
Sorafenib—Nausea—Prednisone—psoriatic arthritis	0.000156	0.000608	CcSEcCtD
Sorafenib—PDGFRA—Allograft Rejection—TNF—psoriatic arthritis	0.000156	0.00171	CbGpPWpGaD
Sorafenib—Pruritus—Methotrexate—psoriatic arthritis	0.000156	0.000605	CcSEcCtD
Sorafenib—FGFR1—Immune System—MEFV—psoriatic arthritis	0.000153	0.00168	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—MEFV—psoriatic arthritis	0.000153	0.00168	CbGpPWpGaD
Sorafenib—Diarrhoea—Methotrexate—psoriatic arthritis	0.00015	0.000585	CcSEcCtD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000149	0.00164	CbGpPWpGaD
Sorafenib—MAPK11—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000149	0.00163	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—REL—psoriatic arthritis	0.000148	0.00162	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—REL—psoriatic arthritis	0.000148	0.00162	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—HLA-B—psoriatic arthritis	0.000147	0.00162	CbGpPWpGaD
Sorafenib—MAP3K7—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	0.000146	0.0016	CbGpPWpGaD
Sorafenib—Dizziness—Methotrexate—psoriatic arthritis	0.000145	0.000565	CcSEcCtD
Sorafenib—RAF1—Downstream signaling in naïve CD8+ T cells—TNF—psoriatic arthritis	0.000144	0.00159	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—HLA-C—psoriatic arthritis	0.000142	0.00156	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—HLA-C—psoriatic arthritis	0.000142	0.00156	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000141	0.00155	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—REL—psoriatic arthritis	0.00014	0.00154	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—REL—psoriatic arthritis	0.00014	0.00154	CbGpPWpGaD
Sorafenib—Vomiting—Methotrexate—psoriatic arthritis	0.00014	0.000544	CcSEcCtD
Sorafenib—Rash—Methotrexate—psoriatic arthritis	0.000139	0.000539	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—psoriatic arthritis	0.000139	0.000539	CcSEcCtD
Sorafenib—Headache—Methotrexate—psoriatic arthritis	0.000138	0.000536	CcSEcCtD
Sorafenib—PDGFRB—Immune System—MEFV—psoriatic arthritis	0.000138	0.00151	CbGpPWpGaD
Sorafenib—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000137	0.00151	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000136	0.00149	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000136	0.00149	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—HLA-C—psoriatic arthritis	0.000135	0.00148	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—HLA-C—psoriatic arthritis	0.000134	0.00147	CbGpPWpGaD
Sorafenib—MAP3K7—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000134	0.00147	CbGpPWpGaD
Sorafenib—Nausea—Methotrexate—psoriatic arthritis	0.000131	0.000508	CcSEcCtD
Sorafenib—FGFR1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000129	0.00142	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000129	0.00141	CbGpPWpGaD
Sorafenib—MAP3K7—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000127	0.00139	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—REL—psoriatic arthritis	0.000126	0.00138	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.000125	0.00137	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MEFV—psoriatic arthritis	0.000123	0.00135	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—HLA-C—psoriatic arthritis	0.000121	0.00133	CbGpPWpGaD
Sorafenib—MAP2K5—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000119	0.00131	CbGpPWpGaD
Sorafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriatic arthritis	0.000119	0.00131	CbGpPWpGaD
Sorafenib—MAPK11—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000116	0.00128	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000116	0.00127	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—NOD2—psoriatic arthritis	0.000116	0.00127	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000114	0.00125	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—REL—psoriatic arthritis	0.000112	0.00123	CbGpPWpGaD
Sorafenib—RAF1—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	0.000111	0.00122	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HLA-C—psoriatic arthritis	0.000108	0.00118	CbGpPWpGaD
Sorafenib—MAP3K7—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000105	0.00115	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—NOD2—psoriatic arthritis	0.000104	0.00114	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—NOD2—psoriatic arthritis	0.000104	0.00114	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000103	0.00114	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—REL—psoriatic arthritis	9.95e-05	0.00109	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—NOD2—psoriatic arthritis	9.89e-05	0.00109	CbGpPWpGaD
Sorafenib—BRAF—MAPK Signaling Pathway—TNF—psoriatic arthritis	9.89e-05	0.00109	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—NOD2—psoriatic arthritis	9.87e-05	0.00108	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	9.62e-05	0.00106	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—HLA-B—psoriatic arthritis	9.3e-05	0.00102	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-C—psoriatic arthritis	9.16e-05	0.00101	CbGpPWpGaD
Sorafenib—MAP3K7—MAPK Signaling Pathway—TNF—psoriatic arthritis	9e-05	0.000988	CbGpPWpGaD
Sorafenib—KIT—Immune System—REL—psoriatic arthritis	8.97e-05	0.000985	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—REL—psoriatic arthritis	8.97e-05	0.000985	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—NOD2—psoriatic arthritis	8.89e-05	0.000976	CbGpPWpGaD
Sorafenib—FGFR1—MAPK Signaling Pathway—TNF—psoriatic arthritis	8.54e-05	0.000938	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—REL—psoriatic arthritis	8.51e-05	0.000935	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—REL—psoriatic arthritis	8.49e-05	0.000932	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—HLA-B—psoriatic arthritis	8.38e-05	0.00092	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—HLA-B—psoriatic arthritis	8.38e-05	0.00092	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-C—psoriatic arthritis	8.26e-05	0.000906	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-C—psoriatic arthritis	8.26e-05	0.000906	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—CRP—psoriatic arthritis	8.22e-05	0.000902	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—HLA-B—psoriatic arthritis	8.05e-05	0.000884	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—HLA-B—psoriatic arthritis	8.05e-05	0.000884	CbGpPWpGaD
Sorafenib—EPHB6—Developmental Biology—TNF—psoriatic arthritis	8.02e-05	0.00088	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—HLA-B—psoriatic arthritis	7.96e-05	0.000873	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—HLA-B—psoriatic arthritis	7.94e-05	0.000871	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—NOD2—psoriatic arthritis	7.92e-05	0.00087	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-C—psoriatic arthritis	7.84e-05	0.00086	CbGpPWpGaD
Sorafenib—MKNK1—Disease—NOS2—psoriatic arthritis	7.82e-05	0.000859	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-C—psoriatic arthritis	7.82e-05	0.000858	CbGpPWpGaD
Sorafenib—FGFR1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	7.71e-05	0.000846	CbGpPWpGaD
Sorafenib—PDGFRA—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	7.69e-05	0.000844	CbGpPWpGaD
Sorafenib—PDGFRB—MAPK Signaling Pathway—TNF—psoriatic arthritis	7.68e-05	0.000843	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—REL—psoriatic arthritis	7.65e-05	0.00084	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—HLA-B—psoriatic arthritis	7.64e-05	0.000839	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HLA-B—psoriatic arthritis	7.62e-05	0.000836	CbGpPWpGaD
Sorafenib—EPHA6—Developmental Biology—TNF—psoriatic arthritis	7.54e-05	0.000828	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—CRP—psoriatic arthritis	7.41e-05	0.000813	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—CRP—psoriatic arthritis	7.41e-05	0.000813	CbGpPWpGaD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	7.26e-05	0.000797	CbGpPWpGaD
Sorafenib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	7.26e-05	0.000797	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—HLA-B—psoriatic arthritis	7.15e-05	0.000785	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-C—psoriatic arthritis	7.04e-05	0.000773	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—CRP—psoriatic arthritis	7.03e-05	0.000772	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—CRP—psoriatic arthritis	7.01e-05	0.00077	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HLA-B—psoriatic arthritis	6.86e-05	0.000754	CbGpPWpGaD
Sorafenib—RAF1—MAPK Signaling Pathway—TNF—psoriatic arthritis	6.84e-05	0.000751	CbGpPWpGaD
Sorafenib—RAF1—Immune System—REL—psoriatic arthritis	6.82e-05	0.000749	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	6.81e-05	0.000748	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	6.81e-05	0.000748	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—NOS2—psoriatic arthritis	6.79e-05	0.000745	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—NOD2—psoriatic arthritis	6.73e-05	0.000739	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	6.47e-05	0.00071	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	6.45e-05	0.000708	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HLA-B—psoriatic arthritis	6.37e-05	0.000699	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—CRP—psoriatic arthritis	6.32e-05	0.000694	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-C—psoriatic arthritis	6.28e-05	0.000689	CbGpPWpGaD
Sorafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	6.17e-05	0.000678	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HLA-B—psoriatic arthritis	6.12e-05	0.000672	CbGpPWpGaD
Sorafenib—KIT—Immune System—NOD2—psoriatic arthritis	6.07e-05	0.000667	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—NOD2—psoriatic arthritis	6.07e-05	0.000667	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—TNF—psoriatic arthritis	5.9e-05	0.000648	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	5.81e-05	0.000638	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NOD2—psoriatic arthritis	5.76e-05	0.000633	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NOD2—psoriatic arthritis	5.75e-05	0.000631	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—NOS2—psoriatic arthritis	5.7e-05	0.000626	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—CRP—psoriatic arthritis	5.63e-05	0.000618	CbGpPWpGaD
Sorafenib—CDK7—Disease—NOS2—psoriatic arthritis	5.51e-05	0.000605	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-B—psoriatic arthritis	5.41e-05	0.000594	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	5.18e-05	0.000569	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NOD2—psoriatic arthritis	5.18e-05	0.000568	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—TNF—psoriatic arthritis	4.9e-05	0.000538	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-B—psoriatic arthritis	4.88e-05	0.000536	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-B—psoriatic arthritis	4.88e-05	0.000536	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—CRP—psoriatic arthritis	4.79e-05	0.000525	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-B—psoriatic arthritis	4.63e-05	0.000509	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-B—psoriatic arthritis	4.62e-05	0.000507	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NOD2—psoriatic arthritis	4.62e-05	0.000507	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HLA-DRB1—psoriatic arthritis	4.58e-05	0.000503	CbGpPWpGaD
Sorafenib—KIT—Immune System—CRP—psoriatic arthritis	4.32e-05	0.000474	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—CRP—psoriatic arthritis	4.32e-05	0.000474	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—TNF—psoriatic arthritis	4.21e-05	0.000462	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-B—psoriatic arthritis	4.16e-05	0.000457	CbGpPWpGaD
Sorafenib—KIT—Immune System—HLA-DRB1—psoriatic arthritis	4.13e-05	0.000454	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HLA-DRB1—psoriatic arthritis	4.13e-05	0.000454	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—CRP—psoriatic arthritis	4.1e-05	0.00045	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—CRP—psoriatic arthritis	4.09e-05	0.000448	CbGpPWpGaD
Sorafenib—BRAF—Disease—NOS2—psoriatic arthritis	3.99e-05	0.000438	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HLA-DRB1—psoriatic arthritis	3.92e-05	0.000431	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HLA-DRB1—psoriatic arthritis	3.91e-05	0.000429	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-B—psoriatic arthritis	3.71e-05	0.000407	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—CRP—psoriatic arthritis	3.68e-05	0.000404	CbGpPWpGaD
Sorafenib—KIT—Disease—NOS2—psoriatic arthritis	3.63e-05	0.000399	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—TNF—psoriatic arthritis	3.6e-05	0.000396	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HLA-DRB1—psoriatic arthritis	3.52e-05	0.000387	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NOS2—psoriatic arthritis	3.45e-05	0.000379	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NOS2—psoriatic arthritis	3.44e-05	0.000378	CbGpPWpGaD
Sorafenib—RAF1—Immune System—CRP—psoriatic arthritis	3.28e-05	0.00036	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HLA-DRB1—psoriatic arthritis	3.14e-05	0.000345	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NOS2—psoriatic arthritis	3.1e-05	0.00034	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	2.91e-05	0.00032	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—TNF—psoriatic arthritis	2.89e-05	0.000317	CbGpPWpGaD
Sorafenib—RAF1—Disease—NOS2—psoriatic arthritis	2.76e-05	0.000303	CbGpPWpGaD
